News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Roche (ROCHE) Inovio (INO) Tysabri Roche (RHHBY) Aimmune Therapeutics (AIMT) Ionis (IONS) KERYX (KERX) Sangamo (SGMO) Biocryst (BCRX) Intercept (ICPT) Dendreon (DNDN) Anadys (ANDS) Idenix (IDIX) Seattle Genetics (SGEN) SERES THERAPEUTICS (MCRB) Jazz Pharmaceuticals (JAZZ) Prosensa (RNA) Sanofi (SNA) Rapamune Genentech galapagos (GLPG) KITE (KITE) GlaxoSmithKline (GSK) ImmunoGen (IMGN) TOKAI (TKAOI) Merck (MRK) AERIE PHARMACEUTICALS Biogen Idec (BIIB) Trastuzumab-DM1 Multiple Myeloma Auspex (ASPX) CompuGen (CGEN) Telaprevir Mirati Therapeutics (MRTX) Valeant Pharmaceuticals International (VRX) ARCA (ABIO) HALOZYME (HALO) VANDA (VNDA) Intermune (ITMN) Ariad (ARIA) Cytokinetics (CYTK) Sarepta (SRPT) Elan (ELN) OSI (OSIP) Theravance (THRX) Micromet (MITI) Velcade (bortezomib) Vitae Pharmaceuticals (VTAE) Revlimid (lenolidamide) Xoma (XOMA) NEKTAR (NKTR)) Array Pharmaceuticals (ARRY) Sanofi (SNY) BIOMARIN (BMRN) Prolor Biotech (PBTH) ZALTRAP™ Abbott Laboratories (ABT) Onyx (ONXX) Herceptin Pluristem (PSTI) ISIS (ISIS) Gilead (GILD) Dynavax (DVAX) Alder Biopharmaceuticals (ALDR) Illumina (ILMN) ADVENTRIX (ANX) Amgen (AMGN) REGULUS (RGLS) Agenus (AGEN SYNTA (SNTA) Benlysta (belimumab) Alnylam (ALNY) Ziofpharm (ZIOP) Agenus (AGEN) Exelixis (EXEL) Zerenex Vertex (VRTX) ACADIA (ACAD) Intrexon (XON) Sequenom (SQNM) Human Genome Sciences (HGSI) C4 Therapeutics Endometrial Cancer NANTKWEST (NK) Regeneron (REGN) ABBVIE (ABBV) Bristol-Myers Squibb (BMY) GUARDIAN HEALTH Anacor (ANAC) JUNO (JUNO) SUNESIS PHARMACEUTICALS (SNSS) Theravance Bio Pharma (TBPH) Human Longevity (HLI) IDERA (IDRA) Galena (GALE) Sanofi-Aventis (SAN) Ridaforolimus Incyte (INCY)